Global Oral Artemether Drugs 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI11246674

Publication Date:

November 14, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Oral artemether refers to oral medications made with artemether as the main ingredient, such as artemether tablets and artemether capsules. Artemether is a medication primarily used for the treatment of malaria. It belongs to the class of drugs known as artemisinin derivatives, which are derived from the plant Artemisia annua (sweet wormwood).
The global Oral Artemether Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (publisher)' newest research report, the 鈥淥ral Artemether Drugs Industry Forecast鈥� looks at past sales and reviews total world Oral Artemether Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Oral Artemether Drugs sales for 2023 through 2029. With Oral Artemether Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Artemether Drugs industry.
This Insight Report provides a comprehensive analysis of the global Oral Artemether Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Artemether Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Oral Artemether Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Artemether Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Artemether Drugs.
United States market for Oral Artemether Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Oral Artemether Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Oral Artemether Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Oral Artemether Drugs players cover Novartis, KPC Pharmaceuticals, Ipca Laboratories, AdvaCare Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Artemether Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Artemether Tablets
Artemether Capsules
Segmentation by Application:
Hospital Pharmacy
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Artemether Tablets
Artemether Capsules
Segmentation by Application:
Hospital Pharmacy
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
KPC Pharmaceuticals
Ipca Laboratories
AdvaCare Pharma

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Oral Artemether Drugs 麻豆原创 Size 2019-2030
2.1.2 Oral Artemether Drugs 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Oral Artemether Drugs by Country/Region, 2019, 2023 & 2030
2.2 Oral Artemether Drugs Segment by Type
2.2.1 Artemether Tablets
2.2.2 Artemether Capsules
2.3 Oral Artemether Drugs 麻豆原创 Size by Type
2.3.1 Oral Artemether Drugs 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Oral Artemether Drugs 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Oral Artemether Drugs Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.5 Oral Artemether Drugs 麻豆原创 Size by Application
2.5.1 Oral Artemether Drugs 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Oral Artemether Drugs 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Oral Artemether Drugs 麻豆原创 Size by Player
3.1 Oral Artemether Drugs 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Oral Artemether Drugs Revenue by Player (2019-2024)
3.1.2 Global Oral Artemether Drugs Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Oral Artemether Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Oral Artemether Drugs by Region
4.1 Oral Artemether Drugs 麻豆原创 Size by Region (2019-2024)
4.2 Global Oral Artemether Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Oral Artemether Drugs 麻豆原创 Size Growth (2019-2024)
4.4 APAC Oral Artemether Drugs 麻豆原创 Size Growth (2019-2024)
4.5 Europe Oral Artemether Drugs 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Oral Artemether Drugs 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Oral Artemether Drugs 麻豆原创 Size by Country (2019-2024)
5.2 Americas Oral Artemether Drugs 麻豆原创 Size by Type (2019-2024)
5.3 Americas Oral Artemether Drugs 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Artemether Drugs 麻豆原创 Size by Region (2019-2024)
6.2 APAC Oral Artemether Drugs 麻豆原创 Size by Type (2019-2024)
6.3 APAC Oral Artemether Drugs 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Oral Artemether Drugs 麻豆原创 Size by Country (2019-2024)
7.2 Europe Oral Artemether Drugs 麻豆原创 Size by Type (2019-2024)
7.3 Europe Oral Artemether Drugs 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral Artemether Drugs by Region (2019-2024)
8.2 Middle East & Africa Oral Artemether Drugs 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Oral Artemether Drugs 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Oral Artemether Drugs 麻豆原创 Forecast
10.1 Global Oral Artemether Drugs Forecast by Region (2025-2030)
10.1.1 Global Oral Artemether Drugs Forecast by Region (2025-2030)
10.1.2 Americas Oral Artemether Drugs Forecast
10.1.3 APAC Oral Artemether Drugs Forecast
10.1.4 Europe Oral Artemether Drugs Forecast
10.1.5 Middle East & Africa Oral Artemether Drugs Forecast
10.2 Americas Oral Artemether Drugs Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Oral Artemether Drugs Forecast
10.2.2 Canada 麻豆原创 Oral Artemether Drugs Forecast
10.2.3 Mexico 麻豆原创 Oral Artemether Drugs Forecast
10.2.4 Brazil 麻豆原创 Oral Artemether Drugs Forecast
10.3 APAC Oral Artemether Drugs Forecast by Region (2025-2030)
10.3.1 China Oral Artemether Drugs 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Oral Artemether Drugs Forecast
10.3.3 Korea 麻豆原创 Oral Artemether Drugs Forecast
10.3.4 Southeast Asia 麻豆原创 Oral Artemether Drugs Forecast
10.3.5 India 麻豆原创 Oral Artemether Drugs Forecast
10.3.6 Australia 麻豆原创 Oral Artemether Drugs Forecast
10.4 Europe Oral Artemether Drugs Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Oral Artemether Drugs Forecast
10.4.2 France 麻豆原创 Oral Artemether Drugs Forecast
10.4.3 UK 麻豆原创 Oral Artemether Drugs Forecast
10.4.4 Italy 麻豆原创 Oral Artemether Drugs Forecast
10.4.5 Russia 麻豆原创 Oral Artemether Drugs Forecast
10.5 Middle East & Africa Oral Artemether Drugs Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Oral Artemether Drugs Forecast
10.5.2 South Africa 麻豆原创 Oral Artemether Drugs Forecast
10.5.3 Israel 麻豆原创 Oral Artemether Drugs Forecast
10.5.4 Turkey 麻豆原创 Oral Artemether Drugs Forecast
10.6 Global Oral Artemether Drugs Forecast by Type (2025-2030)
10.7 Global Oral Artemether Drugs Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Oral Artemether Drugs Forecast
11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Oral Artemether Drugs Product Offered
11.1.3 Novartis Oral Artemether Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 KPC Pharmaceuticals
11.2.1 KPC Pharmaceuticals Company Information
11.2.2 KPC Pharmaceuticals Oral Artemether Drugs Product Offered
11.2.3 KPC Pharmaceuticals Oral Artemether Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 KPC Pharmaceuticals Main Business Overview
11.2.5 KPC Pharmaceuticals Latest Developments
11.3 Ipca Laboratories
11.3.1 Ipca Laboratories Company Information
11.3.2 Ipca Laboratories Oral Artemether Drugs Product Offered
11.3.3 Ipca Laboratories Oral Artemether Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Ipca Laboratories Main Business Overview
11.3.5 Ipca Laboratories Latest Developments
11.4 AdvaCare Pharma
11.4.1 AdvaCare Pharma Company Information
11.4.2 AdvaCare Pharma Oral Artemether Drugs Product Offered
11.4.3 AdvaCare Pharma Oral Artemether Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 AdvaCare Pharma Main Business Overview
11.4.5 AdvaCare Pharma Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.